CCR Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The NCI Center for Cancer Research (CCR) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 27 clinical trials at NIH that match your search criteria

Cancer by type/disease: Lymphoma (Adult)

Trial and Protocol Number Hodgkin Lymphoma	Principal Investigator	Referral Contact
Phase II
A Randomized Phase II Study Of Rituximab With ABVD Versus Standard ABVD for Subjects With Advanced-Stage Classical Hodgkin Lymphoma With Poor Risk Features (IPS Score > 2) NCI-10-C-0050, NCT00654732	Wyndham H. Wilson 301-435-2415	Peggy Shovlin 301-594-6597 mshovlin@mail.nih.gov
Phase I/II
Phase I/II Trial of Yttrium-90-labeled Daclizumab (anti-CD25) Radioimmunotherapy With High-dose BEAM Chemotherapy and Autologous Hematopoietic Stem Cell Rescue in Recurrent and Refractory Hodgkin’s Lymphoma NCI-12-C-0003, NCT01468311	Thomas Waldmann 301-496-6656	Tat’Yana Worthy 301-496-0499 worthyt@mail.nih.gov

Trial and Protocol Number Lymphoma	Principal Investigator	Referral Contact
Phase III
Phase III Randomized Study of R-CHOP Versus Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas NCI-05-C-0252, NCT00118209	Wyndham H. Wilson 301-435-2415	Peggy Shovlin 301-594-6597 mshovlin@mail.nih.gov
Phase II
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC Positive Diffuse Large B-Cell Lymphoma NCI-10-C-0052, NCT01092182	Kieron Dunleavy 301-435-1007	Peggy Shovlin 301-594-6597 mshovlin@mail.nih.gov
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas NCI-10-C-0011, NCT01030900	Wyndham H. Wilson 301-435-2415	Peggy Shovlin 301-594-6597 mshovlin@mail.nih.gov
AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab Leucovorin Rescue and Highly Active Antiretroviral Therapy NCI-06-C-0051, NCT00267865	Robert Yarchoan 301-496-8959	Karen Aleman 301-496-8959 1-800-243-2732 ext. 4 (Toll Free) alemank@mail.nih.gov
Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics NCI-05-C-0170, NCT00114738	Wyndham H. Wilson 301-435-2415	Peggy Shovlin 301-594-6597 mshovlin@mail.nih.gov
Short-Course EPOCH-Rituximab in Untreated CD-20+ HIV-Associated Lymphomas NCI-01-C-0030, NCT00006436	Wyndham H. Wilson 301-435-2415	Peggy Shovlin 301-594-6597 mshovlin@mail.nih.gov
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Patients With Aggressive Non-Hodgkin’s Lymphoma NCI-93-C-0133 (Multi-center study), NCT00001337	Wyndham H. Wilson 301-435-2415	Peggy Shovlin 301-594-6597 mshovlin@mail.nih.gov
Phase I/II
A Phase I/II Study of Tac-Expressing Malignancies (Other than ATL) with Yttrium-90 (90Y)-Radiolabeled Humanized Anti-Tac and Calcium-DTPA NCI-97-C-0110, NCT00019305	Thomas Waldmann 301-496-6656	Tat’Yana Worthy 301-496-0499 worthyt@mail.nih.gov

Trial and Protocol Number Lymphomatoid Granulomatosis	Principal Investigator	Referral Contact
Phase II
Treatment and Natural History Study of Lymphomatoid Granulomatosis NCI-94-C-0074, NCT00018993	Wyndham H. Wilson 301-435-2415	Peggy Shovlin 301-594-6597 mshovlin@mail.nih.gov

Trial and Protocol Number Graft-Versus-Host Disease	Principal Investigator	Referral Contact
Phase II
A Randomized Phase II Single-Center Study of Pomalidomide for Chronic Graft-Versus-Host Disease (GvHD) NCI-12-C-0197, NCT01688466	Steven Z. Pavletic 301-402-4899	Kristen Cole 301-451-6569 colekr@mail.nih.gov
A Randomized Double-Blind Pilot Study of Topical Clobetasol 0.05% Oral Rinse for Oral Chronic Graft-Versus-Host Disease NCI-12-C-0068, NCT01557517	Steven Z. Pavletic 301-402-4899	Kristen Cole 301-451-6569 colekr@mail.nih.gov
No Phase
Prospective Assessment of Clinical and Biological Factors Determining Outcomes in Patients With Chronic Graft-Versus-Host Disease (GVHD) NCI-04-C-0281, NCT00092235	Steven Z. Pavletic 301-402-4899	Zetta Blacklock 301-594-2056 bblacklock@mail.nih.gov

Trial and Protocol Number Hematologic/Blood Cancers	Principal Investigator	Referral Contact
Phase II
Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome NCI-04-C-0055, NCT00074490	Daniel H. Fowler 301-435-8641	Zetta Blacklock 301-594-2056 bblacklock@mail.nih.gov
Phase I/II
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation NCI-09-C-0224, NCT00984165	Nancy M. Hardy 301-451-1406	Zetta Blacklock 301-594-2056 bblacklock@mail.nih.gov
Assessment of the Safety and Feasibility of Administering T cells Expressing an anti-CD19 Chimeric Antigen Receptor to Patients With B-cell Lymphoma or Leukemia NCI-09-C-0082, NCT00924326	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	June A. Kryk 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-Matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders NCI-07-C-0195, NCT00520130	Steven Z. Pavletic 301-402-4899	Zetta Blacklock 301-594-2056 bblacklock@mail.nih.gov
Phase I
Study of the Biology and Natural History of Disease Outcomes in Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies NCI-11-C-0125, NCT01326728	Nancy M. Hardy 301-451-1406	Zetta Blacklock 301-594-2056 bblacklock@mail.nih.gov
Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation NCI-10-C-0054, NCT01087294	James N. Kochenderfer 301-594-5340	Zetta Blacklock 301-594-2056 bblacklock@mail.nih.gov

Trial and Protocol Number Leukemia	Principal Investigator	Referral Contact
Phase II
KW 0761 or Investigator’s Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) NCI-13-C-0069, NCT01626664	Kevin Conlon 301-496-7417	Tat’Yana Worthy 301-496-0499 worthyt@mail.nih.gov

Trial and Protocol Number Solid Tumor	Principal Investigator	Referral Contact
Phase I
A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults With Metastatic Cancers NCI-12-C-0113, NCT01572493	Kevin Conlon 301-496-7417	Tat’Yana Worthy 301-496-0499 worthyt@mail.nih.gov
A Phase I Study of the Hsp90 Inhibitor, PU-H71, in Patients With Refractory Solid Tumors and Low-Grade Non-Hodgkin’s Lymphoma NCI-11-C-0150, NCT01581541	Shivaani Kummar 301-435-0517	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction NCI-11-C-0060, NCT01273155	Shivaani Kummar 301-435-0517	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
Phase I Study of the HSP-90 Inhibitor, AT13387, in Adults With Refractory Solid Tumors NCI-11-C-0029, NCT01245218	Shivaani Kummar 301-435-0517	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas NCI-10-C-0056, NCT01051635	Shivaani Kummar 301-435-0517	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Phase I, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies NCI-09-C-0111, NCT00923520	Susan Bates 301-402-5958	Christine Bryla 301-451-7868 brylacm@mail.nih.gov

For additional studies that may be appropriate for your disease type, please search under Solid Tumor.